We have found that osteocalcin as isolated from bovine bone is nonenzymatically glycosylated. The extent of this glycosylation appears to vary with the age of the animal, perhaps indicating the average turnover time of the deposited bone. Since nonenzymatic glycosylation is also a function of the average glycemic status of the individual, the question arises as to whether or not some of the bone disease associated with diabetes mellitus might reflect abnormal over-glycosylation of bone matrix proteins such as osteocalcin. We intend to examine the levels of bone deposited glycoosteocalcin in the streptozotocin induced diabetic rat. We also intend to develop a RIA for circulating glycoosteocalcin in humans based on monoclonal antibodies raised to glycoosteocalcin. Measurements of osteocalcin will be carried out using the polyclonal antibody to osteocalcin which we have prepared and the RIA employed in our laboratory. The Glycoosteocalcin/Osteocalcin ratio may reflect the turnover of mature bone. Our working hypothesis assumes that newly synthesized osteocalcin is not glycosylated, whereas bone-deposited osteocalcin which turns over will be. Thus, measurement of serum glycoosteocalcin may turn out to be a valuable clinical parameter in the measurement of bone disease and in diabetes. Since amino terminals of long-lifed proteins such as hemoglobin, osteocalcin, serum albumin, LDL-apoprotein and the crystallins become converted in part to N-(1-deoxyfructos-1-yl)-amino terminal residues by nonenzymatic glycosylation, we intend to measure the content of N-(1-deoxyfructos-yl)-amino acids in urine. This measurement could yield information about the turnover of long-lifed proteins in various disease states including diabetes mellitus. We believe that the N-glycotyrosine/N-glycovaline ratio should increase in clinical states characterized by increased bone loss, reflecting, in part, the turnover of glycoosteocalcin normalized by the turnover of glycohemoglobin.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK034369-05
Application #
3232687
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1984-08-01
Project End
1989-07-31
Budget Start
1988-08-01
Budget End
1989-07-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Gallop, P M; Henson, E; Paz, M A et al. (1989) Acid-promoted tautomeric lactonization and oxidation-reduction of pyrroloquinoline quinone (PQQ). Biochem Biophys Res Commun 163:755-63
Strang, C J; Henson, E; Okamoto, Y et al. (1989) Separation and determination of alpha-amino acids by boroxazolidone formation. Anal Biochem 178:276-86
Paz, M A; Gallop, P M; Torrelio, B M et al. (1988) The amplified detection of free and bound methoxatin (PQQ) with nitroblue tetrazolium redox reactions: insights into the PQQ-locus. Biochem Biophys Res Commun 154:1330-7
Fluckiger, R; Woodtli, T; Gallop, P M (1988) The interaction of aminogroups with pyrroloquinoline quinone as detected by the reduction of nitroblue tetrazolium. Biochem Biophys Res Commun 153:353-8